Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125535051 | 12553505 | 1 | I | 201601 | 20160218 | 20160713 | 20160713 | PER | US-PERRIGO-16US001807 | PERRIGO | 66.23 | YR | F | Y | 51.70000 | KG | 20160713 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125535051 | 12553505 | 1 | PS | LANSOPRAZOLE. | LANSOPRAZOLE | 1 | Oral | 15 MG, QD | Y | 5LV0818 | 202319 | 15 | MG | MODIFIED-RELEASE CAPSULE, HARD | |||||
| 125535051 | 12553505 | 2 | C | ZANTAC | RANITIDINE HYDROCHLORIDE | 1 | Unknown | UNK | U | UNKNOWN | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125535051 | 12553505 | 1 | Gastrooesophageal reflux disease |
| 125535051 | 12553505 | 2 | Gastrooesophageal reflux disease |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125535051 | 12553505 | Nausea |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125535051 | 12553505 | 1 | 201601 | 201601 | 0 |